Skip to main content

Validation of a novel class of cyclophilin inhibitors for the treatment of non-alcoholic steatohepatitis

Project description

The first oral drug for a common liver disease may be on the horizon

Non-alcoholic steatohepatitis (NASH), a type of non-alcoholic fatty liver disease, refers to inflammation and damage of the liver caused by a build-up of fat. If NASH gets worse, it can cause scarring of the liver and cirrhosis. Weight loss is recommended in cases of obesity, but there are no medicines to treat it. Cyclophilins are a family of proteins that includes cyclophilin D. Inhibitors of cyclophilin D have been implicated as potential therapeutics but selective, oral agents have been elusive. CYPNASH has discovered a new family of small molecules that inhibit cyclophilins. With expertise in business, pharmaceuticals, and basic research, the team plans to streamline discovery and testing of a suitable NASH therapeutic.

Field of science

  • /social sciences/economics and business

Call for proposal

ERC-2019-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

THE UNIVERSITY OF EDINBURGH
Address
Old College, South Bridge
EH8 9YL Edinburgh
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 150 000

Beneficiaries (1)

THE UNIVERSITY OF EDINBURGH
United Kingdom
EU contribution
€ 150 000
Address
Old College, South Bridge
EH8 9YL Edinburgh
Activity type
Higher or Secondary Education Establishments